

County Durham and Darlington Area Prescribing Committee

Summary of decisions made regarding new product requests considered at a meeting of the Committee on **Thursday 5th July 2018**

Classification of products:

- G** **Green drug** - Can be initiated and prescribed in all care settings **G-** Second line / alternative green drug
- G+** **Green+ drug** Specialist initiation / recommendation. Can be recommended by a specialist for initiation in primary care; or be initiated by a specialist and transferred to primary care once the patient stabilised. In some cases there may be a further restriction for use outlined - these will be defined in each case.
- A** **Amber drug** - These are specialist drugs which must be initiated by the specialist, but with the potential to transfer to primary care within written and agreed shared care protocols and according to the agreed process for transfer of care
- R** **Red drug** - Drugs that should remain under the total responsibility of the specialist. Usually considered as "hospital only" drugs
- X** **Not Approved** - Drugs that have been considered by the APC or other approved body and are not approved for prescribing within County Durham & Darlington.
- ⊘** **Not Reviewed** - Drugs that haven't been reviewed by the APC yet. This usually means that no application has been received or that an application is in progress. These drugs are not normally considered appropriate for prescribing in County Durham & Darlington.
- **Unclassed Drug** - Drugs that do not fall into one of the above categories

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
1) Requests deferred from previous meetings				
None				
2) New Requests				
Insulin Aspart (Fiasp®)	R			<p>Appears to offer some advantage over Novorapid to pregnant patients in terms of tighter blood glucose control</p> <p>Decision: It was agreed to add as a RED drug for use in pregnant patients only for an initial period of 6 months. An audit of hypoglycaemic events, overall glycaemic control and pregnancy outcomes to be brought back to APC at this point. Decisions regarding switching back to Novorapid post-partum will be taken in partnership with patients however this possibility must be clearly explained at the point of switch to Insulin Fiasp.</p>
3) New formulations & extensions to use				
None				

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
5) Products considered by NICE				
TA517: Avelumab for treating metastatic Merkel cell carcinoma	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA518: Tocilizumab for treating giant cell arteritis	✓ R			The formulary will reflect the TAG – CCG is the responsible commissioner
TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy	✓ R			The formulary will reflect the TAG – NHS England is the responsible commissioner.
TA521: Guselkumab for treating moderate to severe plaque psoriasis	✓ R			The formulary will reflect the TAG – CCG is the responsible commissioner
7) Appeals against earlier decisions by the APC				
None				
8) Miscellaneous decisions by the APC				
Standardising strengths of high risk unlicensed anti-TB medicines - Ethambutol 400mg in 5ml, Pyrazinamide 500mg in 5ml, Isoniazid 50mg in 5ml approved to be added to the formulary.	✓ G			Recommended from RMOC to standardise strengths of high risk unlicensed anti-TB medicines. Decision: Agreed to add to formulary

DECISION SUMMARY

Product	Decision			Comments/notes
	Approved	Refused	Deferred	
Sildenafil 25mg & 50mg tablets for Raynaud's	✓ 			Currently has no RAG status on the formulary for this indication. RED status for this indication in keeping with its status in NoT and Tees. This is unlicensed indication. Decision: Agreed to add to formulary as RED drug initially before longterm RAG status agreed at Sept 2018 APC.
Chapter 15 (Anaesthetics)	✓			Decision: New formulary chapter approved.
Levosert 20 micrograms/24 hours Intrauterine Delivery System The intrauterine delivery system contains 52 mg levonorgestrel.				Decision: Update formulary entry to say now licensed for 4 years instead of 3 years.
Tolvaptan				Clarified RAG status and formulary position of Tolvaptan Decision: Entry on the formulary should be updated as follows as per the NoT/Tees formulary: RED - 15mg, 30mg, 45mg, 60mg and 90mg tablets (Jinarc®) - approved for the treatment of autosomal dominant polycystic kidney disease in line with NICE. RED - 15mg and 30mg tablets (Samsca®) - approved for the treatment of hyponatraemia secondary to the Syndrome of Inappropriate Antidiuretic Hormone (SIADH) in patients requiring cancer chemotherapy in accordance with NHS England Policy. NOT APPROVED - 15mg and 30mg tablets (Samsca®) – treatment of hyponatraemia secondary to SIADH. Tolvaptan was rejected by NTAG for this indication and therefore not available in CDD. NHS England – Not routinely commissioned.
Seretide evohaler and accuhaler				Decision: To be removed from formulary as replaced by Sereflo as per CD&D Asthma Guideline.
Fobumix and Fobumix Easyhaler	✓ 			To be used as per CD&D Asthma Guideline. Decision: Agreed to add to formulary
Sereflo MDI	✓ 			To be used as per CD&D Asthma Guideline. Decision: Agreed to add to formulary

The following guidelines were presented to and approved at the July 2018 meeting of the APC:

- CD&D APC Asthma Guidelines – updated
- Trimipramine De-prescribing Guidance
- Dosulepin De-prescribing Guidance – updated
- Continence Formulary

DECISION SUMMARY

- ADHD prescribing algorithm – adults
- ADHD prescribing algorithm – children & young people

The following Green+ drug information leaflets were presented to and approved at the July 2018 meeting of the APC:

- Nil

The following shared care guidelines were presented to and approved at the July 2018 meeting of the APC:

- Lisdexamfetamine, Atomoxetine and Methylphenidate – updated version
- Guanfacine
- Paliperidone LAI and Aripiprazole LAI